4 results
Procedural success, comprising insertion of the Stentys SDS, deployment of the Stentys Sent in the main branch, withdrawal of the Stentys SDS and creation of the Stentys Sent opening for the sidebranch, without major adverse cardiac events during…
We estimate that the anthracycline and cyclophosphamide dose could be significantly (>=15%) increased in at least 15% of ACC-treated patients. Therefore, in order to diminish the risk of under-dosing ACC, we aim to develop a neutrophil-guided…
Primary objectivesDetermine the effect of Sorafenib (Bay 43-9006) on the uptake of In-111 labeled chimeric monoclonal antibody G250 (In-111-cG250) by RCC lesions.Determine the effect of Sorafenib (Bay 43-9006) on the uptake of In-111 labeled…
Primary Safety Objective: To describe the safety profile of 20vPnC